

Datasheet

SERAplex

Defined Serum Replacement

| Produ | Product Description | | Catalogue-No. | Size |
|-------|---------------------|---|--|---------------------------|
| SERAp | olex | Defined serum replacement for adherent and non-adherent cells | ST04-96090 ST04-96900 ST04-96950 | 50 ml 100 ml 500 ml |

Product description

SERAplex is a chemically defined serum replacement for the cultivation of adherent and non-adherent cells under serum-free culture conditions or to significantly reduce the amount of serum in cell culture. It supports the growth of many cell types in an optimum manner without any extra handling compared to serum.

Storage conditions

Storage: -20°C, in the dark

Stability: 2 years from date of production

Size: 50 ml, 100 ml, 500 ml, other sizes on request

Composition

SERAplex contains purified proteins, lipids, salts, amino acids, trace elements, hormones and a 3-dimensional substrate release system in an optimized formulation. It contains no growth factors, undefined hydrolysates or peptones.

Suitability

SERAplex is suitable for the cultivation of a variety of adherent and non-adherent cells under serum-free culture conditions or to reduce the necessary FBS amount in cell culture. (see Fig.1)

Effect of SERAplex in different cell lines




Fig.1 Efficiency and growth stimulation of SERAplex compared to FBS (10% in DMEM/F12) for different cell types

Special advantages



SERAplex is designed to replace or to reduce serum in the cell culture in a very simple manner. In most cases there is no need to change the basal medium. As SERAplex is fully chemically defined and contains no peptones or hydrolysates, lot testing is not necessary anymore. It also allows high reproducibility and simplified downstream process. SERAplex contains no growth factors and enables defined proliferation and differentiation of stem cells. Characterization studies of growth factors will obtain more reproducible and clearer results. SERAplex is also useful to develop sensitive cell-based *in vitro* tests and coculture procedures. For cell lines which require specific growth factors these should be added in a concentration as previously used.

Instructions for use

SERAplex can be stored and used in the same manner as serum.

- Thaw SERAplex at maximum 37 °C. Please avoid repeated freeze-thaw cycles!
- To replace serum: Use the same basal medium and the same concentration of SERAplex as FBS.
 The performance can be further improved by optimizing the concentration of SERAplex or modifying/changing the basal medium^a.
- To reduce serum concentration: Use the same basal medium and add the same amount of SERAplex as the reduced amount of serum, until the minimal necessary concentration of FBS is found (1 to 2.5 % in most cases). The performance can be further improved by optimizing the concentration of SERAplex or modifying/changing the basal medium^a (also see adaptation instructions).
- Recommended inoculation cell density $5 \times 10^4 10 \times 10^4$ cells /ml for non-adherent cells; $5 \times 10^3 20 \times 10^3$ cells/cm² for adherent cells.
- If working with adherent cells: Solve adherent cells as usual from the cell culture vessel (e.g. 0.25% Trypsin, Cat.No. P10-033100 or Accutase[®], Cat.No. ST10-21100). Once the cells have become round and detach from the surface inactivate trypsin with trypsin inhibitor (Cat.No. ST10-034100): Simply resuspend cells in about 1 ml trypsin inhibitor solution for every ml of trypsin solution used for dissociation. Note that Accutase[®] does not need to be inhibited.

Depending on the cell type, some differences in morphology or proliferation rate may be observed with varying standard media. Most applications were performed with RPMI 1640 for non-adherent cells and with DMEM and DMEM/F12 for adherent cells and with these combinations very good growth stimulation was achieved in a range of 5 - 15 % SERAplex.

For demanding cells (e.g. primary cells) an adaptation procedure to serum-free condition may be necessary.

Adaptation instructions for SERAplex

Precondition for a successful transition are vital cells (trypan blue exclusion staining), which should be harvested in the logarithmic growth phase. If 10% FBS was used in the original protocol,

Step 1: 7.5 % FBS + 2.5 % SERAplex

- Seed cells at 5 x 10⁴ 10 x 10⁴ cells/ml (non-adherent cells), or at 5 x 10³ 20 x 10³ cells/cm² (adherent cells).
- Observe cells under a microscope at about 90 % confluence passage the cells for another 2-3 passages.

If normal growth is obtained transfer cells into:



Step 2:5 % FBS + 5 % SERAplex

- Seed cells at 5 x 10⁴ 10 x 10⁴ cells/ml (non-adherent cells), or at 5 x 10³ 20 x 10³ cells/cm² (adherent cells).
- Observe cells under a microscope, at about 90 % confluence passage the cells for another 2-3 passages.

If normal growth is obtained transfer cells into:

Step 3: 2.5 % FBS + 7.5 % SERAplex

- Seed cells at 5 x 10⁴ 10 x 10⁴ cells/ml (non-adherent cells), or at 5 x 10³ 20 x 10³ cells/cm² (adherent cells).
- Observe cells under a microscope, at about 90 % confluence, passage the cells for another 2-3 passages.

If normal growth is obtained transfer cells into:

Step 4: 1 % FBS + 9 % SERAplex

- Seed cells at 5 x 10⁴ 10 x 10⁴ cells/ml (non-adherent cells), or at 5 x 10³ 20 x 10³ cells/cm² (adherent cells).
- Observe cells under a microscope, at about 90 % confluence, passage the cells for another 2-3 passages.

If normal growth is obtained transfer cells into:

Step 5: 10 % SERAplex

- Seed cells at 5 x 10⁴ 10 x 10⁴ cells/ml (non-adherent cells), or at 5 x 10³ 20 x 10³ cells/cm² (adherent cells).
- Observe cells under a microscope.

For some cells an adaptation to serum-free conditions is difficult to reach or even impossible. The following measures may help to facilitate a successful adaptation:

- Reseeding with a higher cell amount (about 2x to 4x of the usual cell density).
- Addition of growth factors (if known, which factors have a positive effect on the relevant cells).
- Coating the culture dishes or flasks with attachment factors (e.g. fibronectin, laminin, collagen, gelatine, etc).
- Change the basal medium. Note: A change of the basal medium to a richer or more complex formulation may be all that is needed to achieve growth in serum free condition.

Table 1: Comparison of Cell Growth in 10% SERAplex in different Basal Media versus Cell Growth in 10% FBS in different Basal Media

| Cell Line | Origin | Basal Medium | Percentage of Growth 10% SERAplex | Percentage of Growth 10% FBS |
|-----------|---------------------|-----------------|---|------------------------------------|
| HEK 293 T | Renal cells, human | DMEM/F12 | 105% | 100% |
| | embryonic | alpha-MEM | 76% | 100 /6 |
| | | DMEM | 62% | |
| MDCK | Renal cells, canine | DMEM/F12 | 102% | 1000/ |
| | | McCoy's 5A | 91% | 100% |
| | | alpha-MEM | 106% | |



| MDBK | Renal cells, bovine | RPMI 1640 | 122% | | |
|--------------|------------------------|-------------|------|--------|--|
| | Tional Jones, Dovine | McCoy's 5A | 135% | 100% | |
| | | DMEM | 131% | | |
| L 929 | Fibroblasts, mouse | DMEM | 97% | | |
| | Tibrobiacto, modo | RPMI 1640 | 78% | 100% | |
| | | Ham's F-12 | 128% | | |
| HT-29 | Colon Carcinoma, | IMDM | 108% | | |
| =- | human | DMEM/F12 | 98% | 100% | |
| | | alpha-MEM | 96% | | |
| HeLa S3 | Cervix carcinoma | Glasgow MEM | 106% | | |
| | epithel, human | IMDM | 72% | 100% | |
| | , | EMEM | 100% | | |
| СНО | Ovarial cells epithel, | DMEM/F12 | 106% | 1000/ | |
| - | Chinese hamster | IMDM | 97% | 100% | |
| | | alpha-MEM | 82% | | |
| CHO-Luc | Ovarial cells epithel, | IMDM | 86% | 4000/ | |
| | Chinese hamster, | DMEM | 97% | 100% | |
| | transfected | alpha-MEM | 84% | | |
| 3T3A | Fibroblasts, mouse | RPMI 1640 | 98% | 1000/ | |
| | | McCoy's 5A | 72% | 100% | |
| | | DMEM/F12 | 97% | | |
| MCF-7 | Mammary | Ham's F-12 | 292% | 1000/ | |
| | carcinoma, human | DMEM/F12 | 176% | 100% | |
| | | RPMI 1640 | 214% | | |
| RAW 264.7 | Macrophages, | McCoy's 5A | 40% | 100% | |
| | mouse | DMEM/F12 | 67% | 100 /6 | |
| | | alpha-MEM | 38% | | |
| U-937 | Lymphoma, human | alpha-MEM | 107% | 100% | |
| | | DMEM/F12 | 15% | 100 /6 | |
| | | DMEM | 20% | | |
| ММ6 | Monocytes, human | RPMI 1640 | 120% | 100% | |
| | | McCoy's 5A | 143% | 10076 | |
| | | DMEM/F12 | 118% | | |
| HL-60 | Promyelocytic | RPMI 1640 | 92% | 100% | |
| | leukemia cells, | DMEM/F12 | 14% | 100 /0 | |
| | human | DMEM | 11% | | |
| X63-Ag8 | Myeloma | DMEM | 94% | 100% | |
| | | RPMI 1640 | 97% | 100 /0 | |
| | | DMEM/F12 | 29% | | |

References

For cell line specific references please see our homepage (www.pan-seratech.com)

Technical support

For technical support, questions or remarks please contact your local PAN-Seratech partner or the technical department of PAN-Seratech via email (info@pan-seratech.com) or phone +49-8543-601630.

FOR RESEARCH USE ONLY! Not approved for human or animal diagnostic or therapeutic procedures.

^a As a basal medium, standard media such as RPMI 1640, DMEM (high or low glucose), DMEM/F12, etc. can be used. Make sure that L-glutamine is present in sufficient quantity (supplement L-glutamine as needed)